Acute Myeloid Leukemias After the Treatment of Classical Hodgkin’s Lymphoma: A Literature Review-Reference-Cited by-同舟云学术

Acute Myeloid Leukemias After the Treatment of Classical Hodgkin’s Lymphoma: A Literature Review

Published:2022 Issue:4 Volume:15 Page:414-423
ISSN:1997-6933
Container-title:Clinical oncohematology
language:
Short-container-title:Клиническая онкогематология

Author:

Danilenko Anatolii Aleksandrovich¹,Shakhtarina S.V.¹,Falaleeva N.A.¹

Affiliation:

1. AF Tsyb Medical Radiological Research Centre, branch of the NMRC of Radiology

Abstract

Second malignant tumors occurring in classical Hodgkin’s lymphoma (cHL) patients after treatment include mainly solid neoplasms and far more rarely acute myeloid leuke-mias (AML). At the same time, a relative risk of developing secondary AML substantially exceeds the risks of second (solid) tumors, and the efficacy of secondary AML treatment is considerably lower compared to the outcomes of primary AML treatment. All that implies the importance and relevance of this issue. The present literature review discusses the epidemiology of developing secondary AMLs in patents after cHL treatment. In addition to that, it focuses on modern drugs and technologies for effective treatment of secondary AMLs.

Publisher

Practical Medicine Publishing House

Subject

Oncology,Hematology

Reference88 articles.

1. Kanzler H., Kuppers R., Hansmann ML, Rajewsky K. Hodgkin and Reed-Sternberg cells in Hodgkin’s disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B. cells. J. Exp Med. 1996;184(4):1495-505. doi: 10.1084/jem.184.4.1495.

2. Devita VT, Serpick AA, Carbone PP. Combination chemotherapy in the treatment of advanced Hodgkin’s disease. Ann Intern Med. 1970;73(6):881-95. doi: 10.7326/0003-4819-73-6-881.

3. Donaldson SS, Hancock SL, Hoppe RT. The Janeway lecture. Hodgkin’s disease-finding the balance between cure and late effects. Cancer J. Sci Am. 1999;5:325-33.

4. Borchmann P., Eichenauer DA, Engert A. State of the art in the treatment of Hodgkin lymphoma. Nat Rev Clin Oncol. 2012;9(8):450-9. doi: 10.1038/nrcli-nonc.2012.91.

5. Federico M., Luminari S., lannitto E., et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin’s lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J. Clin Oncol. 2009;27(5):805-11. doi: 10.1200/JC0.2008.17.0910.